The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countri
Go back to The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countri| Merck & Co. (NYSE: MRK) | Delayed: 148.46 -1.87 (1.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.33 | 52 Week High | $65.46 | |||
| Open | $148.41 | 52 Week Low | $47.97 | |||
| Day High | $149.60 | P/E | 100.99 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 11,184,684 | |||||
